Call | Career Development Fellowship (CDF) |
Programme | EDCTP2 |
Start Date | 2018-06-01 |
End Date | 2021-11-30 |
Project Code | TMA2016CDF1580 |
Status | Completed |
Safety and Efficacy of High Dose Rifampicin in TB-HIV co-infected patients on Efavirenz-based Antiretroviral therapy
Primary objective 1. To determine the effect of a high dose of rifampicin (35 mg/kg orally) on the pharmacokinetics of first-line antiretroviral drugs (efavirenz and dolutegravir) in TB-HIV co-infected patients on TB treatment. Secondary objectives 1. To investigate the safety/tolerability of a high dose of rifampicin in TB-HIV co-infected patients on TB treatment and first-line antiretroviral therapies. 2. To determine if TB-HIV co-infected patients on a high dose of rifampicin are more likely to have negative sputum cultures by the end of the intensive phase of TB treatment than patients on standard-dose rifampicin. 3. To explore the relationships between exposure to rifampicin, efavirenz and dolutegravir and the tolerability and efficacy of these drugs.
Institution | Country |
---|---|
Makerere University - IDI | Uganda |
Randomized four-arm open label clinical trial (Phase IIb) High dose rifampicin will be administered for the first 8 weeks (intensive phase) of TB treatment. All other anti-TB drugs will be administered at the standard dose using fixed-dose combinations (FDC). All participants will receive standard dose rifampicin during the continuation phase (weeks 9 -24)
Title | University | Start Date | End Date |
---|---|---|---|
Correlating rifampcin and isoniazid concentrations with treatment outcomes in TB/HIV co-infected patients | Makerere University/University of Zurich | 2015-07-15 | 2019-05-05 |
Sub-therapeutic rifampicin and isoniazid concentrations in up to 84% of population which was associated with delayed sputum conversion No association between drug concentrations and sputum smear conversion is not surprising Efavirenz associated with 20% increase in isoniazid clearance
PMC7020342 |
Infectious Diseases Institute
Post-doc researcher
2018 | Stephen Lawn Research TB-HIV Research Leadership Award |
Type | Name | Title | University | Start Date | End Date |
---|
Role | Committee/board | Start Date | End Date |
---|
Institution | Degree | Year |
---|---|---|
Makerere University, Uganda | MBChB | 2006-06-01 |
Makerere University, Uganda | Masters in Internal Medicine | 2012-07-01 |
Makerere University/University of Zurich, Uganda | PHD | 2018-09-01 |
Human Immuno-deficiency Virus (HIV) Tuberculosis (TB)